利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.043 秒)

    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION
    4.
    发明公开
    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
    抗氧化药物组合物

    公开(公告)号：EP2470178A1

    公开(公告)日：2012-07-04

    申请号：EP10744747.6

    申请日：2010-07-29

    申请人： Pola Pharma Inc. ,  Nihon Nohyaku Co., Ltd.

    发明人： KOBAYASHI, Hirokazu ,  KUBOTA, Nobuo

    IPC分类号： A61K31/4178 ,  A61P17/00 ,  A61P31/10 ,  A61K47/08

    CPC分类号： A61K31/4178 ,  A61K9/0014 ,  A61K47/08 ,  A61P17/00 ,  A61P31/10

    摘要： A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R1═R2=a chlorine atom: where R1 and R2 each independently represents a hydrogen atom or a halogen atom, and at least one of R1 and R2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.

    摘要翻译： 1。一种药物组合物，其含有1）下述通式（1）表示的化合物和/或其盐; 和2）酮如甲乙酮。 优选地，下述通式（1）表示的化合物为卢立康唑，其中R 1 = R 2 =氯原子：其中R 1和R 2各自独立地表示氢原子或卤素原子，且R 1且R 2表示卤素原子。 本发明提供一种在低温或高温储存下对由通式（1）表示的化合物和/或其盐的溶解稳定性优异的制剂。

    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION
    6.
    发明公开
    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 审中-公开
    抗真菌的药物组合物

    公开(公告)号：EP2416757A2

    公开(公告)日：2012-02-15

    申请号：EP10714490.9

    申请日：2010-04-09

    申请人： Pola Pharma Inc. ,  Nihon Nohyaku CO., LTD.

    发明人： KOBAYASHI, Hirokazu ,  KOSUGI, Eiko ,  KUBOTA, Nobuo

    IPC分类号： A61K9/08

    CPC分类号： A61K31/4178 ,  A61K9/0014 ,  A61K9/08 ,  A61K9/7015 ,  A61K47/08 ,  A61K47/10 ,  A61K47/14

    摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60° C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture.

    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION
    8.
    发明公开
    ANTIMYCOTIC PHARMACEUTICAL COMPOSITION 有权
    抗生素药物ZUSAMMENSETZUNG

    公开(公告)号：EP2416758A2

    公开(公告)日：2012-02-15

    申请号：EP10714491.7

    申请日：2010-04-09

    申请人： Pola Pharma Inc. ,  Nihon Nohyaku CO., LTD.

    发明人： KOBAYASHI, Hirokazu ,  KOSUGI, Eiko ,  KUBOTA, Nobuo

    IPC分类号： A61K9/08

    CPC分类号： A61K9/7015 ,  A61K9/0014 ,  A61K9/08 ,  A61K31/4178

    摘要： In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25°C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a steroisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20°C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5°C. for 2 weeks after manufacture.

    摘要翻译： 在含有诸如卢立康唑和/或其盐的化合物的外用药物组合物中，包括在1大气压和25℃下处于液体状态的高级醇和/或二元酸的二酯， 排除碳酸二酯，聚氧乙烯烷基醚和/或聚氧乙烯烯基醚。 本发明提供使用克罗他米通以外的溶剂，碳酸丙烯酯和N-甲基-2-吡咯烷酮作为增溶和空间稳定化的溶剂的制剂，具有以下性质：1）当由通式（1）表示的化合物和 /或其盐具有立体异构体，在60℃的保存条件下生产的化合物和/或其盐的立体异构体的量为3周时相对于总质量为1质量％ 该化合物和/或其盐在保存开始时; 2）制备后立即在20°C的恒温下保存时，制剂处于透明液体状态; 和3）当制剂在制备后在5℃下保存2周后，不沉积晶体。